Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28771670 | 0.90 | TLR8 (0.59) | TLR8TLR7 | |
| SCHEMBL1239780 | 0.87 | TLR8 (0.69) | TLR8TLR7 | |
| SCHEMBL22777464 | 0.83 | TLR8 (0.59) | TLR8TLR7 | |
| SCHEMBL28771849 | 0.82 | TLR8 (0.63) | TLR8TLR7 | |
| SCHEMBL22770869 | 0.82 | TLR8 (0.54) | TLR8TLR7 | |
| SCHEMBL22771001 | 0.82 | TLR8 (0.60) | TLR8TLR7 | |
| SCHEMBL1588511 | 0.80 | TLR8 (0.60) | TLR8TLR7 | |
| SCHEMBL22770868 | 0.80 | TLR8 (0.58) | TLR8TLR7 | |
| SCHEMBL22771193 | 0.79 | TLR8 (0.55) | TLR8TLR7 | |
| SCHEMBL21413440 | 0.77 | TLR8 (0.78) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983082-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3983080-A1 | MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS | Bolt Biotherapeutics, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020252254-A1 | MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252294-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20200390899-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390899-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | IDO2, IDO1, BCR | TLR8 3275/4885TLR7 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.